Stocks and Investing Stocks and Investing
Mon, November 1, 2021
Sun, October 31, 2021
Sat, October 30, 2021
Fri, October 29, 2021
Thu, October 28, 2021

Michael Schmitz Maintained (BPMC) at Strong Buy with Increased Target to $122 on, Oct 28th, 2021


Published on 2024-10-27 18:22:28 - WOPRAI, Michael Schmitz
  Print publication without navigation


Michael Schmitz of Guggenheim, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $120 to $122 on, Oct 28th, 2021.

Michael has made no other calls on BPMC in the last 4 months.



There is 1 other peer that has a rating on BPMC. Out of the 1 peers that are also analyzing BPMC, all agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $96 on, Friday, July 30th, 2021